Compare Booz Allen Hamilton Holding Corporation (BAH) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Booz Allen Hamilton Holding Corporation vs Pfizer Inc — how do they compare? Booz Allen Hamilton Holding Corporation trades at $64.01 (market cap $7.62B), while Pfizer Inc trades at $24.27 (market cap $138.21B). The key difference: Pfizer Inc is far larger — about 18.1× Booz Allen Hamilton Holding Corporation's market cap, and Pfizer Inc pays the higher dividend (7.09%). Which is the better fit depends on your goals.
| BAH | PFE | |
|---|---|---|
Market Cap | $7.62B | $138.21B |
Sector | Industrials | Health |
52-Week High | $115.95 | $28.56 |
52-Week Low | $59.71 | $23.29 |
Enterprise Value | $11.02B | $188.87B |
Dividend Yield | 3.71% | 7.09% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Booz Allen Hamilton (BAH) trades at $64.80, up 3.25% in the last session, with a bearish technical signal but strong fundamentals including a P/E of 9.39 and net income margin of 7.59%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. The company announced a partnership with OpenAI and an acquisition to bolster its defense technology portfolio, signaling strategic growth in AI and national security sectors.
Outlook is mixed: analyst consensus price target of $78.17 suggests 20% upside, supported by robust cash flow and government contracts, but risks include high debt levels and market volatility. The stock's current price near the low end of analyst targets indicates potential value, though technical indicators warn of short-term pressure.
Pfizer (PFE) trades at $24.25, up 0.33% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.75, beating expectations, and maintains a dividend of $0.43 per share. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, with key catalysts expected in 2026. Financials show revenue of $62.58B in 2025, with a net income margin of 11.83% and a P/E ratio of 18.69.
The outlook for Pfizer is mixed, with analyst consensus leaning toward Hold (58.98%) but a price target of $28.78 suggesting potential upside. Investment opportunities include a strong dividend yield and pipeline advancements, while risks involve patent cliffs and competitive pressures. The stock's current valuation appears reasonable, but execution on pipeline developments is critical for future growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
